-
Something wrong with this record ?
Thyroid Cancer Detection in a Routine Clinical Setting: Performance of ACR TI-RADS, FNAC, and Molecular Testing in Prospective Cohort Study
T. Grimmichova, P. Pacesova, M. Hill, B. Pekova, M. Vankova, J. Moravcova, J. Vrbikova, Z. Novak, K. Mastnikova, E. Vaclavikova, J. Vcelak, B. Bendlova, J. Drozenova, V. Sykorova
Language English Country Switzerland
Document type Journal Article
Grant support
AZV (NU21-01-00448)
Government of the Czech Republic
EU 00023761
Government of the Czech Republic
NLK
Directory of Open Access Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
The aim of our study was to address the potential for improvements in thyroid cancer detection in routine clinical settings using a clinical examination, the American College of Radiology Thyroid Imaging Reporting and Database System (ACR TI-RADS), and fine-needle aspiration cytology (FNAC) concurrently with molecular diagnostics. A prospective cohort study was performed on 178 patients. DNA from FNA samples was used for next-generation sequencing to identify mutations in the genes BRAF, HRAS, KRAS, NRAS, and TERT. RNA was used for real-time PCR to detect fusion genes. The strongest relevant positive predictors for malignancy were the presence of genetic mutations (p < 0.01), followed by FNAC (p < 0.01) and ACR TI-RADS (p < 0.01). Overall, FNAC, ACR TI-RADS, and genetic testing reached a sensitivity of up to 96.1% and a specificity of 88.3%, with a diagnostic odds ratio (DOR) of 183.6. Sensitivity, specificity, and DOR decreased to 75.0%, 88.9%, and 24.0, respectively, for indeterminate (Bethesda III, IV) FNAC results. FNA molecular testing has substantial potential for thyroid malignancy detection and could lead to improvements in our approaches to patients. However, clinical examination, ACR TI-RADS, and FNAC remained relevant factors.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017345
- 003
- CZ-PrNML
- 005
- 20241111144447.0
- 007
- ta
- 008
- 220718s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biomedicines10050954 $2 doi
- 035 __
- $a (PubMed)35625691
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Grimmichova, Tereza $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $u Internal Clinic, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Srobarova 1150/50, 10034 Prague, Czech Republic $1 https://orcid.org/000000022355540X
- 245 10
- $a Thyroid Cancer Detection in a Routine Clinical Setting: Performance of ACR TI-RADS, FNAC, and Molecular Testing in Prospective Cohort Study / $c T. Grimmichova, P. Pacesova, M. Hill, B. Pekova, M. Vankova, J. Moravcova, J. Vrbikova, Z. Novak, K. Mastnikova, E. Vaclavikova, J. Vcelak, B. Bendlova, J. Drozenova, V. Sykorova
- 520 9_
- $a The aim of our study was to address the potential for improvements in thyroid cancer detection in routine clinical settings using a clinical examination, the American College of Radiology Thyroid Imaging Reporting and Database System (ACR TI-RADS), and fine-needle aspiration cytology (FNAC) concurrently with molecular diagnostics. A prospective cohort study was performed on 178 patients. DNA from FNA samples was used for next-generation sequencing to identify mutations in the genes BRAF, HRAS, KRAS, NRAS, and TERT. RNA was used for real-time PCR to detect fusion genes. The strongest relevant positive predictors for malignancy were the presence of genetic mutations (p < 0.01), followed by FNAC (p < 0.01) and ACR TI-RADS (p < 0.01). Overall, FNAC, ACR TI-RADS, and genetic testing reached a sensitivity of up to 96.1% and a specificity of 88.3%, with a diagnostic odds ratio (DOR) of 183.6. Sensitivity, specificity, and DOR decreased to 75.0%, 88.9%, and 24.0, respectively, for indeterminate (Bethesda III, IV) FNAC results. FNA molecular testing has substantial potential for thyroid malignancy detection and could lead to improvements in our approaches to patients. However, clinical examination, ACR TI-RADS, and FNAC remained relevant factors.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pacesova, Petra $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
- 700 1_
- $a Hill, Martin $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/0000000217050835 $7 mzk2005304431
- 700 1_
- $a Peková Bulanová, Barbora, $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/000000028571164X $d 1993- $7 xx0256338
- 700 1_
- $a Vankova, Marketa $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/0000000318837274
- 700 1_
- $a Moravcova, Jitka $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/0000000317050744
- 700 1_
- $a Vrbikova, Jana $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
- 700 1_
- $a Novak, Zdenek $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
- 700 1_
- $a Mastnikova, Karolina $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
- 700 1_
- $a Vaclavikova, Eliska $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
- 700 1_
- $a Vcelak, Josef $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
- 700 1_
- $a Bendlova, Bela $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic
- 700 1_
- $a Drozenova, Jana $u Department of Pathology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Srobarova 1150/50, 10034 Prague, Czech Republic
- 700 1_
- $a Sykorova, Vlasta $u Institute of Endocrinology, Narodni 8, 11694 Prague, Czech Republic $1 https://orcid.org/0000000234491472
- 773 0_
- $w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 10, č. 5 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35625691 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220718 $b ABA008
- 991 __
- $a 20241111144444 $b ABA008
- 999 __
- $a ind $b bmc $g 1816548 $s 1168587
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 10 $c 5 $e 20220420 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
- GRA __
- $a AZV (NU21-01-00448) $p Government of the Czech Republic
- GRA __
- $a EU 00023761 $p Government of the Czech Republic
- LZP __
- $a Pubmed-20220718